Musical chairs at GSK leaves Stout out

You can take your $4 million and keep it. David Stout (photo), GlaxoSmithKline's president of pharmaceutical operations, evidently wants no part of the reported $4 million incentive package he was offered after being passed up for the top job. The company reported this morning that he's on the way out, while another frustrated candidate, Chris Viehbacher (photo), president of U.S. pharmaceuticals, joins the board. No word yet on where Stout may land. Andrew Witty (photo), new chief, also took his place on the board. And Eddie Gray, currently senior vice president and general manager pharmaceuticals UK, will succeed Witty as president, pharmaceuticals Europe.

- check out the release on the executive moves

Related Articles:
GSK runners-up get $4M, board seat. Report
GSK CEO also-rans may get on board. Report
At GSK, a public race for the top spot. Report
Just who is Glaxo's Andrew Witty? Report
GSK taps Witty as next CEO. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.